What Patients with Advanced Cancer Experience As Helpful in Navigating Their Life with a Long-term Response: a Qualitative Study
Overview
Authors
Affiliations
Purpose: Despite improved survival for people with advanced cancer due to new medical treatments, a growing group of long-term responders (LTRs) has to learn to live with uncertainties that affect several life domains. At the core of their experience, they neither feel like a patient nor feel healthy. Despite growing awareness of LTRs' experiences, learning more about how they cope with their long-term response can provide insight into how to best support them. Our study aimed to gain a deeper understanding what LTRs experience as helpful in navigating life with a long-term response.
Methods: We conducted an exploratory qualitative study using thematic data analysis. Semi-structured in-depth interviews were conducted with 17 participants with advanced melanoma or lung cancer with confirmed response or long-term stable disease while on immuno- or targeted therapy.
Results: LTRs reported several strategies to navigate life with a long-term response, for example, by involving the social environment, seeing uncertainty as an opportunity, and being present in the moment. This helped them to reclaim a sense of control, alter their perspective, and reshape their lives according to their values.
Conclusion: Using different coping strategies enables LTRs to acknowledge both their sick and healthy side. Striking a healthy balance between being oriented on feeling sick or feeling healthy can help LTRs and their close others to navigate life with a long-term response. Healthcare professionals can provide support by recognizing whether LTRs are oriented at feeling sick or healthy, and by actively involving close others during medical appointments.
Kolsteren E, Deuning-Smit E, Prins J, van der Graaf W, Kwakkenbos L, Custers J J Cancer Surviv. 2024; .
PMID: 39470942 DOI: 10.1007/s11764-024-01698-w.
Kamminga N, Kievits J, Wakkee M, van Loon S, Joosen M, Verver D Arch Dermatol Res. 2024; 316(9):645.
PMID: 39325191 PMC: 11427545. DOI: 10.1007/s00403-024-03376-4.
Schellekens M, Zwanenburg L, van der Lee M Curr Oncol. 2024; 31(7):4003-4014.
PMID: 39057169 PMC: 11276221. DOI: 10.3390/curroncol31070297.
Vanlaer N, Dirven I, Neyns B, Rogiers A Cancers (Basel). 2024; 16(9).
PMID: 38730590 PMC: 11083145. DOI: 10.3390/cancers16091638.